IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or the "Company") today announced a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Split") and
Gainers
Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.